Search / Trial NCT06236334

ELFI Health (e-Health for Empowerment by Lifestyle, Food Advice and Interaction)

Launched by TNO · Jan 23, 2024

Trial Information

Current as of October 03, 2024

Recruiting

Keywords

Lifestyle E Health Behavior

Description

In the Netherlands about 1,2 million people are living with type 2 diabetes. This number increases weekly by an average of 1000 people. Besides, an equal number of people are living in a condition of prediabetes. In this precondition of type 2 diabetes, prevention is still possible for people by changing their lifestyle. Ideally, for every individual a personalised lifestyle intervention, adapted to the individual situation, biology and preferences is advised. A personalised lifestyle intervention is effective in preventing and delaying progression to type 2 diabetes. In this study, it will...

Gender

ALL

Eligibility criteria

  • Inclusion Criteria:
  • 1. Healthy as assessed with screening questionnaire
  • 2. HbA1c: 39 - 53 mmol/mol (= 5.7 - 7.0%)
  • 3. Age between 18 - 70 years
  • 4. Stable BMI of 25 - 35 kg/m2
  • 5. Informed consent signed
  • 6. Willing to comply with the study procedures during the study
  • 7. Being able to become more physically active, as assessed by the screening questionnaire (P9885 F02; in Dutch).
  • 8. Being digitally competent
  • 9. Willing to accept the use of all nameless data, including publication, and the confidential use and storage of all data for at least 15 years
  • Exclusion Criteria:
  • 1. Being diagnosed with diabetes type 1 or 2
  • 2. Use of insulin, corticosteroids (systemic), or beta-blockers in past month
  • 3. Use of oral diabetes medication in past year
  • 4. (Having a history of a) medical condition that might significantly affect the study outcome as judged by the general practitioner and health and lifestyle questionnaire. This includes gastrointestinal dysfunction, diseases related to inflammation or allergy, or a psychiatric disorder
  • 5. Being abroad or on vacation for longer than a week.
  • 6. Alcohol consumption \> 21 (women) - 28 (men) units/week
  • 7. Reported unexplained weight loss or gain of \> 2 kg in the month prior to the pre-study screening
  • 8. Recent blood donation (\<1 month prior to the start of the study)
  • 9. Not willing to give up blood donation during the study
  • 10. Not willing to accept information-transfer concerning participation in the study, or information regarding his health, like laboratory results, findings at anamnesis or physical examination and eventual adverse events to and from his general practitioner.
  • 11. Pregnant or lactating women
  • 12. Involved in another Combined Lifestyle Intervention or weight loss program
  • 13. On GLP-1 analogues to stimulate weight loss

About Sponsor

The National Institute of Allergy and Infectious Diseases (NIAID, /ˈnaɪ.æd/) is one of the 27 institutes and centers that make up the National Institutes of Health (NIH), an agency of the United States Department of Health and Human Services (HHS). NIAID's mission is to conduct basic and applied research to better understand, treat, and prevent infectious, immunologic, and allergic diseases.

Contacts

JC

Jennifer Cobb

Immunology at National Institute of Allergy and Infectious Diseases (NIAID)

Locations

Leiden, Holland, Netherlands

People applied

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported

Discussion 0